Dr. Olderman Highlights Value of Bonded Antimicrobial at Textiles Conference
Gainesville, FL, February 12, 2008 --(PR.com)-- Quick-Med Technologies (OTCBB: QMDT)’s Vice President of Research & Development and Commercialization, Gerald M. Olderman, Ph.D., presented “Unique and New: A Bonded Antimicrobial Concept,” at the recent Summit Session on Antimicrobials in Plastic and Textile Applications Conference.
Dr. Olderman’s presentation showcased the multiple advantages of Quick-Med Technologies’ patented NIMBUS® antimicrobial technology and emphasized the uniqueness of a bonded antimicrobial.
NIMBUS is the only commercially available antimicrobial technology in which a large, multi-active polymer is permanently bonded to any of a number of base materials. NIMBUS is an acronym for Novel Intrinsic Micro-Bonded Utility Substrate.
Ordinary commercial antimicrobials work by “releasing” or “leaching” their active agents. Sooner or later, this results in depletion of the agent which has several significant drawbacks including loss of antimicrobial protection and an increase in likelihood of spawning antimicrobial resistance (i.e. so called “super bugs”) as levels drop below the levels needed for effective microbial kill rates. Because NIMBUS is permanently bonded and does not deplete, it will not fall below the level needed to achieve inactivation (kill microbes) and thus avoids the potential for bacteria to develop a resistance.
Studies conducted by the company, as well as by independent laboratories, demonstrate that NIMBUS is highly effective, including against Methicillin-resistant Staphylococcus aureus (“MRSA”) and Vancomycin-resistant Enterococcus (“VRE”), two of the most significant antibiotic-resistant organisms responsible for hospital-acquired and community-acquired infections.
Previous attempts to offer a “bonded” antimicrobial have been limited to small molecules which are not capable of the strong permanent bonding achieved by NIMBUS. These prior materials can be adequate for short-duration uses where strong, long-lasting performance is not required. However, the relatively small size of the molecule means that they are also prone to being blinded or otherwise loosing effectiveness in high challenge applications.
The powerful breakthrough NIMBUS® antimicrobial technology offers many other benefits that arise out of its permanence on the substrate. Because it remains at a fixed level of concentration, it especially lends itself to reusability and repeated launderability, even high levels of commercial or industrial laundering. NIMBUS is well suited for the many applications where persistent, extended action is required such as wound care, active and intimate apparel, and textiles for the healthcare and hospitality industries. And because NIMBUS was originally developed for wound care applications, it maintains its effectiveness in the presence of blood, body fluids and other “high-challenge” situations.
Another benefit of the permanence of NIMBUS technology in wound care applications is the fact that because it is bound it cannot enter a wound and interfere with healing NIMBUS provides safe, effective, long-lasting, and environmentally-responsible antimicrobial technology at a fraction of the cost of today’s leading antimicrobials.
About Dr. Gerald M. Olderman
Dr. Olderman is the Vice President of Research & Development and Commercialization of Quick-Med Technologies, and a member of the Company’s Board of Directors. Dr. Olderman has over 35 years in the healthcare industry including 25 years as head of research and development for major product divisions of three fortune 500 companies. Dr. Olderman received a B.S in Chemistry from Rensselaer Polytechnic Institute and an M.S. and Ph.D. in Physical Chemistry from Seton Hall University.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see:www.quickmedtech.com.
Safe Harbor for Forward-Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Quick-Med Technologies, Inc. intends that such forward looking statements be subject to the safe harbor created thereby. Quick-Med Technologies, Inc. does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
###
Dr. Olderman’s presentation showcased the multiple advantages of Quick-Med Technologies’ patented NIMBUS® antimicrobial technology and emphasized the uniqueness of a bonded antimicrobial.
NIMBUS is the only commercially available antimicrobial technology in which a large, multi-active polymer is permanently bonded to any of a number of base materials. NIMBUS is an acronym for Novel Intrinsic Micro-Bonded Utility Substrate.
Ordinary commercial antimicrobials work by “releasing” or “leaching” their active agents. Sooner or later, this results in depletion of the agent which has several significant drawbacks including loss of antimicrobial protection and an increase in likelihood of spawning antimicrobial resistance (i.e. so called “super bugs”) as levels drop below the levels needed for effective microbial kill rates. Because NIMBUS is permanently bonded and does not deplete, it will not fall below the level needed to achieve inactivation (kill microbes) and thus avoids the potential for bacteria to develop a resistance.
Studies conducted by the company, as well as by independent laboratories, demonstrate that NIMBUS is highly effective, including against Methicillin-resistant Staphylococcus aureus (“MRSA”) and Vancomycin-resistant Enterococcus (“VRE”), two of the most significant antibiotic-resistant organisms responsible for hospital-acquired and community-acquired infections.
Previous attempts to offer a “bonded” antimicrobial have been limited to small molecules which are not capable of the strong permanent bonding achieved by NIMBUS. These prior materials can be adequate for short-duration uses where strong, long-lasting performance is not required. However, the relatively small size of the molecule means that they are also prone to being blinded or otherwise loosing effectiveness in high challenge applications.
The powerful breakthrough NIMBUS® antimicrobial technology offers many other benefits that arise out of its permanence on the substrate. Because it remains at a fixed level of concentration, it especially lends itself to reusability and repeated launderability, even high levels of commercial or industrial laundering. NIMBUS is well suited for the many applications where persistent, extended action is required such as wound care, active and intimate apparel, and textiles for the healthcare and hospitality industries. And because NIMBUS was originally developed for wound care applications, it maintains its effectiveness in the presence of blood, body fluids and other “high-challenge” situations.
Another benefit of the permanence of NIMBUS technology in wound care applications is the fact that because it is bound it cannot enter a wound and interfere with healing NIMBUS provides safe, effective, long-lasting, and environmentally-responsible antimicrobial technology at a fraction of the cost of today’s leading antimicrobials.
About Dr. Gerald M. Olderman
Dr. Olderman is the Vice President of Research & Development and Commercialization of Quick-Med Technologies, and a member of the Company’s Board of Directors. Dr. Olderman has over 35 years in the healthcare industry including 25 years as head of research and development for major product divisions of three fortune 500 companies. Dr. Olderman received a B.S in Chemistry from Rensselaer Polytechnic Institute and an M.S. and Ph.D. in Physical Chemistry from Seton Hall University.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see:www.quickmedtech.com.
Safe Harbor for Forward-Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Quick-Med Technologies, Inc. intends that such forward looking statements be subject to the safe harbor created thereby. Quick-Med Technologies, Inc. does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
###
Contact
Quick-Med Technologies, Inc.
Natasha Sorobey
888.835.2211
www.quickmedtech.com
Natasha Sorobey
888.835.2211
www.quickmedtech.com
Contact
Categories